ScholarIQanswers from OpenAlex & ORCID
Xuezhi Hao
ResearcherPublications, citations & collaboration network
Xuezhi Hao is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Xuezhi Hao have?
ScholarIQindexed works
Xuezhi Hao has 192 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Xuezhi Hao have?
ScholarIQcitation count
Xuezhi Hao has 1,665 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Xuezhi Hao?
ScholarIQh-index
Xuezhi Hao has an h-index of 24 in OpenAlex.
What is the i10-index of Xuezhi Hao?
ScholarIQi10-index
Xuezhi Hao has an i10-index of 56 in OpenAlex.
What is the ORCID of Xuezhi Hao?
ScholarIQorcid
The ORCID for Xuezhi Hao is on the source record.
What is the OpenAlex record for Xuezhi Hao?
ScholarIQopenalex
The OpenAlex for Xuezhi Hao is on the source record.
What are the most-cited papers on Xuezhi Hao?
ScholarIQmost cited works
Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes
Yuxin Mu, Xuezhi Hao, Puyuan Xing, Xingsheng Hu, Yan Wang, Li Teng, Jinyao Zhang, Ziyi Xu, Junling Li
miR-130a regulates macrophage polarization and is associated with non-small cell lung cancer
Lin Lin, Haibo Lin, Lin Wang, Bin Wang, Xuezhi Hao, Yuankai Shi
Survival and pretreatment prognostic factors for extensive‐stage small cell lung cancer: A comprehensive analysis of <scp>358</scp> patients
Li‐Ling Huang, Xingsheng Hu, Yan Wang, Junling Li, Hongyu Wang, Peng Liu, Jianping Xu, Xiao‐Hui He, Xuezhi Hao, Pei‐Di Jiang, Yutao Liu, Jian Luo, Shengyu Zhou, Jin‐Wan Wang, Jian‐Liang Yang, Yan Qin, Peng Yuan, Lin Lin, Yuankai Shi
Comprehensive Profiling of Gene Copy Number Alterations Predicts Patient Prognosis in Resected Stages I–III Lung Adenocarcinoma
Xiaohong Han, Qiaoyun Tan, Sheng Yang, Junling Li, Jianping Xu, Xuezhi Hao, Xingsheng Hu, Puyuan Xing, Yutao Liu, Lin Lin, Lin Gui, Yan Qin, Jianliang Yang, Peng Liu, Xingyuan Wang, Wumin Dai, Dongmei Lin, Hua Lin, Yuankai Shi
Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer
Yan Sun, Ying Cheng, Xuezhi Hao, Jie Wang, Chengping Hu, Baohui Han, Xiaoqing Liu, Li Zhang, Huiping Wan, Zhongjun Xia, Yunpeng Liu, Wei Li, Mei Hou, Helong Zhang, Qingyu Xiu, Yunzhong Zhu, Jifeng Feng, Shukui Qin, Xiaoyan Luo